Mambet et al. [14] showed that patients with essential thrombocythemia (ET) carrying JAK2-R1063H and JAK2-V617F mutations had increased JAK2 signaling and disease severity, with 28% of them experiencing thrombotic events. The gene discussed is JAK2; the disease is essential thrombocythemia.